PDF(Pubmed)
Abstract：
Posterior reversible encephalopathy syndrome (PRES) is an uncommon transient neuroradiological phenomenon that develops vasogenic cerebral edema and could be caused by some pharmacological agents, such as molecular-specific target agents. Lenvatinib belongs to the tyrosine kinase inhibitors and was approved in 2015 for progressive locally advanced or metastatic thyroid cancer refractory to radioactive iodine (I-131) treatment. Herein, we present the case of a 65-year-old woman who, while receiving treatment with lenvatinib for radioiodine-refractory metastatic papillary thyroid carcinoma, developed PRES without hypertension at the initial evaluation. Her clinical and radiological findings improved after withdrawing from the mentioned therapy, and later it was possible to re-incorporate lower doses of the medication, as described in the other three case reports found in the worldwide medical literature. The recognition of this entity is essential to timely suspend the drug and avoid greater comorbidity. This is the first paper reporting this kind of adverse event using lenvatinib in a Hispanic population.
摘要：
后部可逆性脑病综合征（PRES）是一种罕见的短暂性神经放射学现象，可引起血管源性脑水肿，可由某些药物引起。如分子特异性靶试剂。Lenvatinib属于酪氨酸激酶抑制剂，并于2015年被批准用于放射性碘（I-131）治疗难治性进行性局部晚期或转移性甲状腺癌。在这里，我们介绍一个65岁的女人，在接受lenvatinib治疗放射性碘难治性转移性甲状腺乳头状癌的同时，在初始评估时发展为PRES，无高血压。退出上述治疗后，她的临床和放射学检查结果有所改善，后来有可能重新掺入较低剂量的药物，正如在全球医学文献中发现的其他三例病例报告中所描述的那样。对该实体的识别对于及时中止药物和避免更大的合并症至关重要。这是第一篇在西班牙裔人群中使用lenvatinib报告这种不良事件的论文。
